Your session is about to expire
← Back to Search
Bone Graft Substitute
Test for Tibial Fracture
N/A
Waitlist Available
Led By Douglas R. Dirschl, MD
Research Sponsored by BONESUPPORT AB
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to demonstrate the safety and effectiveness of CERAMENT™\|G used in conjunction with standard-of-care treatment compared to standard-of-care treatment alone in the care of subjects with open fractures of the tibial diaphysis.
Eligible Conditions
- Tibial Fracture
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Composite of absence of deep infection at fracture site, absence of secondary procedures intended to promote fracture union, and improvement in the SF-36v2 PCS.
Serious device related adverse events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TestExperimental Treatment2 Interventions
Tibial fracture fixation with IM Nail. Apply CERAMENT™\|G applied to bony void(s).
Group II: ControlActive Control1 Intervention
Tibial fracture fixation with IM nail.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CERAMENT|G
2017
N/A
~210
SOC treatment
2017
N/A
~210
Find a Location
Who is running the clinical trial?
BONESUPPORT ABLead Sponsor
4 Previous Clinical Trials
553 Total Patients Enrolled
Douglas R. Dirschl, MDPrincipal InvestigatorThe University of Chicago Medicine
Share this study with friends
Copy Link
Messenger